A randomised controlled trial of EP395, a novel anti-inflammatory macrolide, in stable COPD patients
Henrik Watz, Stephanie Korn, Oliver Kornmann, Dave Singh, Tom Wilkinson, Kate Hanrott, Karl J. Staples, Jodie Ackland, Virginia Norris · 2026
Read A randomised controlled trial of EP395, a novel anti-inflammatory macrolide, in stable COPD patients by Henrik Watz, Stephanie Korn, Oliver Kornmann, Dave Singh, Tom Wilkinson, Kate Hanrott, Karl J. Staples, Jodie Ackland, Virginia Norris (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13202357.txt.
Description
Long-term macrolide antibiotics calm lung inflammation but breed resistance, and a 2026 randomized trial headed by Henrik Watz tests a new macrolide designed to avoid that trade-off. The phase 2a trial evaluates EP395, also called glasmacinal, in patients with stable chronic obstructive pulmonary disease over twelve weeks of daily treatment.
Sixty-one patients were assigned to the drug or placebo, and the drug was well tolerated with similar adverse event rates in both groups. Sputum markers of neutrophil activation fell with treatment, including a marked drop in neutrophil elastase levels. Sequencing found no detectable effect on the lung microbiome, backing further growth of the resistance-sparing concept.
Catalog record
| CREATOR | Henrik Watz, Stephanie Korn, Oliver Kornmann, Dave Singh, Tom Wilkinson, Kate Hanrott, Karl J. Staples, Jodie Ackland, Virginia Norris |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |